NeOnc Technologies to meet FDA Nov. 17 for End-of-Phase 1 discussion on NEO212

NeOnc Technologies announced an in-person End-of-Phase 1 Type B meeting with the FDA on Nov. 17, 2026 to discuss NEO212 development.Key Highlights:Original SEC Filing: NEONC TECHNOLOGIES HOLDINGS, INC. [ NTHI ] - 8-K - Sep. 28, 2026This is an AI-powered summary. It may contain inaccuracies. Conside…